Saranas, Inc., has announced initiation and first patient enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety of complex high-risk percutaneous coronary intervention (PCI) using mechanical circulatory support (MCS) and surveillance with its Early Bird Bleed Monitoring System (“Early Bird”).

Baird Capital led the Houston-based company’s $12.8 million Series B fundraise. Saranas is a privately held medical device company focusing on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented Early Bird for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeds immediately before they become complications, improving patient outcomes and lowering healthcare costs. The Early Bird remains the first and only device of its kind. 

Learn more about the most recent announcement here.